Table 1 Baseline patient characteristics.
From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
| Overall | All patients enrolled(N = 115) |
|---|---|
| Age, years | 53.53(±8.69) |
| Data for front-line treatment in this study | |
| The tumor origin | |
| Ovary | 107 (93.0%) |
| Fallopian tube | 6 (5.2%) |
| Peritoneum | 1 (0.9%) |
| unknown | 1 (0.9%) |
| Pathologic histology type | |
| Serous Tumors | 108 (93.9%) |
| High-grade | 91 (84.3%) |
| Low-grade | 8 (7.4%) |
| Unknown | 9 (8.3%) |
| Mucinous Tumors | 1 (0.9%) |
| Endometrioid Tumors | 1 (0.9%) |
| Clear Cell Tumors | 4 (3.5%) |
| Mixed epithelial tumors | 1 (0.9%) |
| FIGO stage | |
| I | 1 (0.9%) |
| II | 4 (3.5%) |
| III | 97 (84.3%) |
| IIIA | 10 (10.3%) |
| IIIB | 10 (10.3%) |
| IIIC | 74 (76.3%) |
| Unknown | 3 (3.1%) |
| IV | 13 (11.3%) |
| IVA | 3 (23.1%) |
| IVB | 6 (46.2) |
| Unknown | 4 (30.7%) |
| Primary cytoreductive surgery | 59 (51.3%) |
| Interval cytoreductive surgery | 56 (48.7%) |
| Residual disease | |
| Optimal cytoreductive surgery | |
| No gross residual disease (R0) | 50 (43.5%) |
| <1 cm but visible residual disease | 46 (40.0%) |
| Suboptimal cytoreductive | 16 (13.9%) |
| Unknown | 3 (2.6%) |
| Previous chemotherapy cycles | |
| < 6 | 16 (13.9%) |
| 6–9 | 92 (80.0%) |
| > 9 | 2 (1.7%) |
| Unknown | 5 (4.3%) |
| The previous response status to platinum-based chemotherapy | |
| Platinum-refractory | 36 (31.3%) |
| Platinum-resistant relapse | 31 (27.0%) |
| Partially platinum- sensitive relapse | 48 (41.7%) |
| Data before this study | |
| CA125, U/ml | 183.90 (72.27–430.65; 6.00–7135.00) |
| ECOG | |
| 0 | 63 (54.8%) |
| 1 | 46 (40.0%) |
| 2 | 6 (5.2%) |